Navigation Links
Nausea Drug Shows Promise Against Opioid Addiction
Date:2/18/2009

Ondansetron relieves withdrawal symptoms without side effects, early study shows

WEDNESDAY, Feb. 18 (HealthDay News) -- A drug currently used to treat nausea can prevent symptoms of withdrawal from illegal and prescription opioid drugs such as heroin, morphine and codeine, a new study shows.

The Stanford University scientists behind the research added it can do so without some of the serious side effects caused by existing treatments for addiction to these drugs.

Initial tests in mice showed that the drug ondansetron (Zofran) blocks certain 5-HT3 receptors involved in withdrawal symptoms, the researchers said. They then tested it in eight healthy, non-opioid-dependent volunteers who were given two doses of morphine, once without ondansetron and one with it, and found ondansetron reduced withdrawal symptoms in humans.

The study appears in the Feb. 17 online issue of the Journal of Pharmacogenetics and Genomics.

"Opioid abuse is rising at a faster rate than any other type of illicit drug use, yet only about a quarter of those dependent on opioids seek treatment. One barrier to treatment is that when you abruptly stop taking the drugs, there is a constellation of symptoms associated with withdrawal," lead author Dr. Larry F. Chu, an assistant professor of anesthesia, said in a Stanford news release.

Those symptoms include agitation, insomnia, diarrhea, nausea and vomiting. Current methods of treating withdrawal symptoms aren't completely effective or cause severe side effects, requiring constant patient supervision.

"What we need is a magic bullet, something that treats the symptoms of withdrawal, does not lead to addiction and can be taken at home," Chu added.

The Stanford team plans to continue testing the effectiveness of ondansetron in treating opioid addiction and to conduct a clinical study to determine the effectiveness of an ondansetron-like drug in treating opioid addiction.

However, the researchers noted that ondansetron alone can't solve the problems caused by opioid addiction, which is a long-term, complex process that involves both physical and psychological factors.

"This is not a cure for addiction. It's naive to think that any one receptor is a panacea for treatment. Treating the withdrawal component is only one way of alleviating the suffering. With luck and determination, we can identify additional targets and put together a comprehensive treatment program," principal investigator Dr. J. David Clark, a professor of anesthesia, said in the news release.

More information

The National Institutes of Health has more about opiate withdrawal.



-- Robert Preidt



SOURCE: Stanford University, news release, Feb. 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
2. SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
3. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
4. Explaining chemotherapy-associated nausea
5. Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary
6. Acupuncture does not reduce radiotherapy-induced nausea, but patients believe it does
7. No Link Between Anti-Nausea Drug, Heart Trouble
8. HotHead Technologies Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers
9. Partnership for Prevention: CDC Report Shows Compelling Need for FDA Regulation of Tobacco
10. New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products
11. Caregivers not receiving the help they need, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nausea Drug Shows Promise Against Opioid Addiction
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans ... important that we all are aware of our options and are empowered with ... announce the launch of its newest edition of "Vision and Hearing" in USA ...
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... The ... 2017 national conference convening academic faculty engaged in or interested in palliative care education ... Research,” will be held in North County San Diego on Sept. 28 and ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business ... in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Worth Hotel in Fort Worth, Texas. Nine awards are given out in five categories. ...
(Date:2/23/2017)... ... 2017 , ... Thinksport, the most award-winning sunscreen on the ... Marin. For the second year in a row, cyclists will stay protected from ... thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts again ...
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology: